Real-time enrollment status for this relapsed and/or refractory multiple myeloma clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 2:06 PM UTC
| NCT Number | NCT06153251 |
| Recruiting Status | Recruiting |
| Condition | Relapsed and/or Refractory Multiple Myeloma |
| Phase | Clinical Trial |
| Target Enrollment | 187 participants |
| Active Locations | 13 sites in the US |
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Last Updated on CT.gov | March 18, 2026 (Mar 18, 2026) |
As of July 13, 2026: Clinical trial NCT06153251 is currently recruiting participants. This clinical trial study for relapsed and/or refractory multiple myeloma is actively seeking new participants at 13 locations across the United States. The study is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06153251 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 13 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06153251 was last updated Mar 18, 2026 (March 18, 2026). HelloStudys verifies this status automatically.